TABLE 3.
Presentation of clinical parameters at visit 1 and visit 2
| Parameter | Controls (n = 26) Mean ± SD (range) | EPs 7630 (n = 26) |Mean ± SD (range) | Roxithromycin (n = 26) Mean ± SD (range) | P value Kruskal‐Wallis test |
|---|---|---|---|---|
| NO | ||||
| Visit 1 | 6.5 ± 0.6 (5‐7) | 6.5 ± 0.6 (5‐7) | 6.5 ± 0.6 (5‐7) | .975 |
| Visit 2 | 6.9 ± 0.3 (5‐7) | 3.1 ± 0.4 (2‐4) | 2.1 ± 0.7 (2‐3) | <.001 |
| RH | ||||
| Visit 1 | 6.4 ± 0.9 (4‐7) | 6.5 ± 0.6 (5‐7) | 6.6 ± 0.5 (6‐7) | .768 |
| Visit 2 | 6.9 ± 0.3 (6‐7) | 3.4 ± 0.8 (2‐5) | 3.5 ± 0.8 (2‐5) | <.001 |
| PD | ||||
| Visit 1 | 6.6 ± 0.6 (5‐7) | 6.4 ± 0.6 (5‐7) | 6.5 ± 0.6 (5‐7) | .624 |
| Visit 2 | 6.8 ± 0.4 (6‐7) | 3.0 ± 0.6 (2‐4) | 2.9 ± 0.7 (2‐5) | <.001 |
| FPP | ||||
| Visit 1 | 6.5 ± 0.8 (5‐7) | 6.5 ± 0.5 (6‐7) | 6.7 ± 0.7 (4‐7) | .147 |
| Visit 2 | 6.6 ± 0.6 (6‐7) | 3.0 ± 0.3 (2‐4) | 2.1 ± 0.6 (2‐4) | <.001 |
| LSS | ||||
| Visit 1 | 6.4 ± 0.8 (5‐7) | 6.6 ± 0.6 (5‐7) | 6.4 ± 0.6 (5‐7) | .384 |
| Visit 2 | 6.8 ± 0.5 (6‐7) | 3.1 ± 0.5 (2‐3) | 2.0 ± 0.6 (1‐3) | <.001 |
| TSS | ||||
| Visit 1 | 32.3 ± 2.0 (29‐35) | 32.5 ± 1.6 (28‐35) | 32.7 ± 1.8 (29‐35) | .701 |
| Visit 2 | 34.0 ± 1.0 (32‐35) | 15.9 ± 1.2 (12‐20) | 12.3 ± 2.0 (10‐15) | <.001 |
| TES | ||||
| Visit 1 | 10.6 ± 1.0 (9‐12) | 10.9 ± 0.9 (9‐12) | 10.4 ± 0.8 (9‐12) | .085 |
| Visit 2 | 11.8 ± 0.4 (11‐12) | 5.9 ± 0.7 (5‐7) | 3.8 ± 0.7 (3‐5) | <.001 |
| ME | ||||
| Visit 1 | 5.3 ± 0.8 (4‐6) | 5.8 ± 0.4 (5‐6) | 5.6 ± 0.5 (5‐6) | .046 |
| Visit 2 | 5.8 ± 0.4 (5‐6) | 2.9 ± 0.4 (2‐4) | 2.1 ± 0.5 (2‐3) | <.001 |
| MS | ||||
| Visit 1 | 5.3 ± 0.8 (4‐6) | 5.2 ± 0.7 (4‐6) | 4.8 ± 0.7 (4‐6) | .102 |
| Visit 2 | 5.9 ± 0.3 (4‐6) | 3.0 ± 0.6 (2‐4) | 1.8 ± 0.5 (1‐3) | <.001 |
Abbreviations: FPP, facial pain/pressure; LSS, loss of sense of smell; ME, mucosal edema; MS, mucopurulent secretion; NO, nasal obstruction; PD, postnasal drip; RH, rhinorrhea; TES, total endoscopic score; TSS, total symptom score.